## FasL Antibody Cell Signaling 0rders: 877-616-CELL (2355) orders@cellsignal.com Support: 877-678-TECH (8324) Web: info@cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W	Reactivity: H	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 26, 40	<b>Source/Isotype:</b> Rabbit	<b>UniProt ID:</b> #P48023	Entrez-Gene Id: 356
Product Usage Information		Application Western Blotting			Dilution 1:1000	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.				
Specificity/Sensitivity		FasL Antibody detects endogenous levels of total FasL protein. The antibody is expected to react with both membrane bound and soluble forms of FasL. No cross reactivity was detected with other family members.				
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding proline 134 of human FasL. Antibodies were purified by protein A and peptide affinity chromatography.				
Background		Association of the receptor Fas with its ligand FasL triggers an apoptotic pathway that plays an important role in immune regulation, development, and progression of cancers (1,2). Loss of function mutation in either Fas (lpr mice) or FasL (gld mice) leads to lymphadenopathy and splenomegaly as a result of decreased apoptosis in CD4-CD8- T lymphocytes (3,4). FasL (CD95L, Apo-1L) is a type II transmembrane protein of 280 amino acids (runs at approximately 40 kDa upon glycosylation) that belongs to the TNF family, which also includes TNF-q, TRAIL, and TWEAK. Binding of FasL to its receptor triggers the formation of a death-inducing signaling complex (DISC) involving the recruitment of the adaptor protein FADD and caspase-8 (5). Activation of caspase-8 from this complex initiates a caspase cascade resulting in the activation of caspase-3 and subsequent cleavage of proteins leading to apoptosis. Unlike Fas, which is constitutively expressed by various cell types, FasL is predominantly expressed on activated T lymphocytes, NK cells, and at immune privileged sites (6). FasL is also expressed in several tumor types as a mechanism to evade immune surveillance (7). Similar to other members of the TNF family, FasL can be cleaved by metalloproteinases producing a 26 kDa trimeric soluble form (8,9).				
Background References		1. Suda, T. et al. (1993) <i>Cell</i> 75, 1169-78. 2. Lee, H.O. and Ferguson, T.A. (2003) <i>Cytokine Growth Factor Rev</i> 14, 325-35. 3. Watanabe-Fukunaga, R. et al. (1992) <i>Nature</i> 356, 314-7. 4. Hahne, M. et al. (1995) <i>Int Immunol</i> 7, 1381-6. 5. Nagata, S. (1997) <i>Cell</i> 88, 355-65. 6. Green, D.R. and Ferguson, T.A. (2001) <i>Nat Rev Mol Cell Biol</i> 2, 917-24. 7. Walker, P.R. et al. (1997) <i>J Immunol</i> 158, 4521-4. 8. Kayagaki, N. et al. (1995) <i>J Exp Med</i> 182, 1777-83. 9. Tanaka, M. et al. (1995) <i>EMBO J</i> 14, 1129-35.				
Species Reacti	ivitv	Species reactivity is d	etermined by testin	g in at least one approve	ed application (e.g.,	western blot).
Western Blot Buffer		IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.				
Applications Key		W: Western Blotting				
Cross-Reactivity Key		H: Human				
Trademarks and Patents		Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.				
		All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.				

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.